We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "24096"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T16:00:34.487Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pancreatin"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what information her Department holds on the availability of Creon 25000 across the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4640", "label" : {"_value" : "Biography information for David Linden"} } , "tablingMemberConstituency" : {"_value" : "Glasgow East"} , "tablingMemberPrinted" : [{"_value" : "David Linden"} ], "uin" : "24095"} , {"_about" : "http://data.parliament.uk/resources/1714568", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714568/answer", "answerText" : {"_value" : "
We are aware of ongoing intermittent supply issues with Creon 25000 gastro-resistant capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The supplier has confirmed that stock of Creon 25000 gastro resistant capsules is now available, with further deliveries scheduled in May 2024. The Department has issued guidance to healthcare professionals regarding treatment of patients, while there was disruption to the supply of Creon 25000 gastro-resistant capsules. We continue to explore all management options to manage this issue. We have asked the supplier to continue confirming their future forecasts, and to inform us of any further gaps in supply of Creon 25000 gastro-resistant capsules.<\/p>
Whilst we can\u2019t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with the suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "24095"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T16:00:34.537Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Shortages"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) mitigate potential future shortages of (i) Creon 25000 and (ii) other essential medicines and (b) ensure that people affected by medicine shortages have access to alternative options.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4640", "label" : {"_value" : "Biography information for David Linden"} } , "tablingMemberConstituency" : {"_value" : "Glasgow East"} , "tablingMemberPrinted" : [{"_value" : "David Linden"} ], "uin" : "24096"} , {"_about" : "http://data.parliament.uk/resources/1714027", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714027/answer", "answerText" : {"_value" : "
The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency\u2019s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE\u2019s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE\u2019s recommendations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T08:57:40.253Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sipavibart"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"} } , "tablingMemberConstituency" : {"_value" : "Christchurch"} , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"} ], "uin" : "23829"} , {"_about" : "http://data.parliament.uk/resources/1714079", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714079/answer", "answerText" : {"_value" : "
Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.<\/p>
The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T09:02:05.22Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Gabapentin"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "23890"} , {"_about" : "http://data.parliament.uk/resources/1714094", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714094/answer", "answerText" : {"_value" : "
NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.<\/p>
In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England\u2019s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.<\/p>
To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times.\u202fThe centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.<\/p>
In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "23908"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T08:52:14.653Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Heart Diseases: Surgery"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4571", "label" : {"_value" : "Biography information for Gill Furniss"} } , "tablingMemberConstituency" : {"_value" : "Sheffield, Brightside and Hillsborough"} , "tablingMemberPrinted" : [{"_value" : "Gill Furniss"} ], "uin" : "23907"} , {"_about" : "http://data.parliament.uk/resources/1714095", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714095/answer", "answerText" : {"_value" : "
NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.<\/p>
In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England\u2019s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.<\/p>
To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times.\u202fThe centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.<\/p>
In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "23907"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T08:52:14.607Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Heart Diseases: Women"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4571", "label" : {"_value" : "Biography information for Gill Furniss"} } , "tablingMemberConstituency" : {"_value" : "Sheffield, Brightside and Hillsborough"} , "tablingMemberPrinted" : [{"_value" : "Gill Furniss"} ], "uin" : "23908"} , {"_about" : "http://data.parliament.uk/resources/1714139", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714139/answer", "answerText" : {"_value" : "
The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff.<\/p>
There are a number of key national programmes aimed at supporting regions, integrated care boards (ICBs), and providers with recruitment challenges, and growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment, encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.<\/p>
The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICS), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, thereby reducing NHS staff leaver rates.<\/p>
<\/p>
Support for organisations and ICS can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues to support the retention agenda in each of the seven regions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T11:26:40.5Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Health Professions: Labour Turnover"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she has had with Integrated Care Boards on recruitment and retention of health workers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "tablingMemberConstituency" : {"_value" : "Bristol South"} , "tablingMemberPrinted" : [{"_value" : "Karin Smyth"} ], "uin" : "23888"} , {"_about" : "http://data.parliament.uk/resources/1714143", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714143/answer", "answerText" : {"_value" : "
Tackling cancer is a key priority for the Government. Ministers and officials continue to work closely with NHS England to increase positive outcomes for all cancer types, including pancreatic cancer. The National Health Service is delivering a range of interventions expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to arrange diagnostic tests.<\/p>
<\/p>
NHS England is also funding a new audit into pancreatic cancer to increase the consistency of access to treatments, and to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024. In addition to this, the Getting it Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions NHS providers need to take to improve services, as well as gathering examples of good practice to share.<\/p>
The NHS is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-05-01T09:23:30.103Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pancreatic Cancer: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on progress on improving outcomes for patients suffering from pancreatic cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1500", "label" : {"_value" : "Biography information for Theresa Villiers"} } , "tablingMemberConstituency" : {"_value" : "Chipping Barnet"} , "tablingMemberPrinted" : [{"_value" : "Theresa Villiers"} ], "uin" : "23840"} , {"_about" : "http://data.parliament.uk/resources/1713607", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1713607/answer", "answerText" : {"_value" : "
The NHS Long Term Workforce Plan sets out how to improve culture and leadership, to ensure that up to 130,000 fewer staff leave the National Health Service over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICSs), regions, NHS trusts, and organisations to improve employee experience to retain their people, and therefore reduce NHS staff leaver rates.<\/p>
<\/p>
The National Retention Programme provides a suite of evidence-based, targeted, organisational-level interventions, to improve staff engagement and experience, in line with the NHS People Promise. The programme builds on the fundamentals that every organisation should be developing to support a good working environment, providing practical advice and support. It targets activities at the key career points at which staff are most likely to leave, to help improve retention.<\/p>
<\/p>
Support for organisations and ICSs can be accessed via the Retention Hub,\u202fwhich outlines initiatives mapped against the NHS People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues support the retention agenda in each of the seven regions. Further information on the Retention Hub is available at the following link:<\/p>
<\/p>
https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-05-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-05-01T10:52:50.083Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Integrated Care Systems: Labour Turnover"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking ensure Integrated Care Schemes are able to support staff retention schemes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4653", "label" : {"_value" : "Biography information for Stephen Morgan"}
}
, "tablingMemberConstituency" : {"_value" : "Portsmouth South"}
, "tablingMemberPrinted" : [{"_value" : "Stephen Morgan"}
], "uin" : "23563"}
, {"_about" : "http://data.parliament.uk/resources/1713068", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713068/answer", "answerText" : {"_value" : " The standards of training for health care professionals are the responsibility of the health care independent statutory regulatory bodies, including the General Medical Council (GMC), the Nursing and Midwifery Council, and the Health and Care Professions Council. These have the general function of promoting high standards of education, and co-ordinating all stages of education, to ensure that health and care students and newly qualified health care professionals are equipped with the knowledge, skills, and attitudes essential for professional practice, including knowledge of cerebral palsy.<\/p> The training curricula for postgraduate specialty training is set by the relevant royal college, and has to meet the standards set by the GMC.\u202fWhilst curricula do not necessarily highlight specific conditions for doctors to be aware of, they do emphasise the skills and approaches that a doctor must develop in order to ensure accurate and timely diagnoses and treatment plans for their patients.<\/p> The National Institute for Health and Care Excellence (NICE) has also published a range of guidance on care and support for children and young people, and adults with cerebral palsy, to support health care professionals and commissioners. The guidance outlines the kind of specialist care that children, young people, and adults with cerebral palsy may need from health and social care professionals. The guidance document for children and young people with cerebral palsy, and the guidance document for adults with cerebral palsy, are available respectively at the following links:<\/p> https://www.nice.org.uk/guidance/ng62<\/a><\/p>